Literature DB >> 17126952

Gastrin 1-6 promotes growth of colon cancer cells through non-CCK receptors.

Jeffrey Copps1, Shawn Ahmed, Richard F Murphy, Sándor Lovas.   

Abstract

Our previous studies have shown that stimulation of proliferation of DLD-1 and HT29 human colonic cancer cells by nanomolar gastrin (G17) and carboxymethyl gastrin (G17Gly) and reversal of growth by micromolar G17 and G17Gly involves binding sites which can neither be CCK1 nor CCK2 receptors; the N terminal fragment, G17(1-12), is sufficient to increase the number of HT-29 cells by binding the higher affinity binding site but is without a suppressing effect through the lower affinity site. In this study with DLD-1 cells, competitive binding using 125I-G17(1-12) showed that G17(1-12) binds both high and low affinity sites, as do G17 and G17Gly. G17(1-6)-NH2, even without the central-to-C-terminal portion of G17, was still able to bind a single site and to promote a dose-dependent increase in cell number at nanomolar concentrations. The results indicate the presence of a non-CCK receptor on human colonic cancer cells which could mediate the tumor-promoting activity of the N-terminal-to-central portion of G17Gly which, unlike G17, is produced by such cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126952     DOI: 10.1016/j.peptides.2006.10.008

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

Review 1.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

2.  The structure of bioactive analogs of the N-terminal region of gastrin-17.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Peptides       Date:  2009-09-18       Impact factor: 3.750

3.  Bioactivity of analogs of the N-terminal region of gastrin-17.

Authors:  Jeffrey Copps; Shawn Ahmed; Richard F Murphy; Sándor Lovas
Journal:  Peptides       Date:  2009-09-15       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.